Sinovac Biotech (SVA) Given Daily Coverage Optimism Rating of 0.11
News headlines about Sinovac Biotech (NASDAQ:SVA) have trended somewhat positive this week, according to Accern Sentiment. The research group rates the sentiment of news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Sinovac Biotech earned a media sentiment score of 0.11 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 45.9564995453523 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Shares of Sinovac Biotech (SVA) traded up $0.06 on Friday, hitting $8.00. The stock had a trading volume of 74,900 shares, compared to its average volume of 105,075. The firm has a market cap of $456.09, a P/E ratio of 25.00 and a beta of 0.13. Sinovac Biotech has a 12 month low of $4.60 and a 12 month high of $8.11.
Separately, BidaskClub downgraded Sinovac Biotech from a “buy” rating to a “hold” rating in a research note on Wednesday.
ILLEGAL ACTIVITY WARNING: “Sinovac Biotech (SVA) Given Daily Coverage Optimism Rating of 0.11” was published by Watch List News and is owned by of Watch List News. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this news story can be accessed at https://www.watchlistnews.com/sinovac-biotech-sva-given-daily-coverage-optimism-rating-of-0-11/1804621.html.
About Sinovac Biotech
Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps.
Receive News & Ratings for Sinovac Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinovac Biotech and related companies with MarketBeat.com's FREE daily email newsletter.